Leveragen的动态

We are thrilled to announce our strategic partnership with Leveragen, a leader in cutting-edge humanized mouse models, to advance antibody discovery to new heights! ?? This collaboration merges Leveragen’s Singularity Sapiens Mouse, an advanced platform for producing fully human single-domain antibodies, with DPBIO’s Cytospark? droplet microfluidic single-B cell antibody discovery platform. Together, we aim to redefine the antibody discovery process. ?? Key Benefits of This Partnership: ? Unmatched Efficiency: Cytospark? delivers high-throughput precision, significantly reducing screening time while maintaining superior accuracy. ? Revolutionary Diversity: The Singularity Sapiens Mouse generates human antibodies with exceptional affinity, diversity, and stability, solving critical bottlenecks in traditional approaches. ? Accelerating Innovation: By combining our technologies, we are uniquely positioned to address complex therapeutic targets and propel the development of next-generation biologics. This collaboration reflects our shared mission to push the boundaries of antibody discovery and bring transformative therapies to life. To learn more, check out the official announcement here: https://lnkd.in/ewY8YA5P #AntibodyTherapeutics #AntibodyEngineering #AntibodyDiscovery

In more business news, AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, announced the expansion of a previous agreement with Gilead Sciences, Inc. to develop novel antibody discovery technologies and discover therapeutic antibodies for Gilead-selected targets. Under the initial agreement in June 2023, AbTherx received worldwide rights to Atlas? Mice, a suite of transgenic mouse technologies acquired by Gilead, and committed to a multi-year, multi-target research collaboration. In just over a year, AbTherx established a world-class research center and successfully developed transgenic mouse technologies that express the full diversity of human antibody HC and k-LC repertoires and enable the development of bispecific antibodies through a novel binary fixed light chain. AbTherx is also continuing development of a technology that uses natural mechanisms to generate long CDRH3 antibodies to address challenging drug targets (e.g., GPCRs and ion channels) that was part of the original agreement. Under the expanded agreement, AbTherx will develop and receive worldwide rights to additional transgenic technologies and broaden the multi-year, multi-target research collaboration to include the performance of additional therapeutic antibody research programs. #mabs https://lnkd.in/exFsH-BQ

We continue to feature the most popular and impactful articles published in 2023 in our journal, Antibody Therapeutics (2022 CiteScore: 6.4). The title of the 9th article we’d like to feature is “Alpaca single B cell interrogation and heavy-chain-only antibody discovery on an optofluidic platform”. In vivo VHH discovery approaches have been limited by the lack of methodologies for camelid B cell interrogation. The authors at Twist Bioscience reported a novel application of the Beacon? optofluidic platform to the discovery of heavy-chain-only antibodies by screening alpaca B cells. The first and co-corresponding author is Mariya Shapiro, and the other co-corresponding author is Colby Souders who is currently CSO of BrickBio, Inc. ? Antibody Therapeutics (2022 CiteScore: 6.4) is the official journal of Chinese Antibody Society (CAS), a non-profit, non-government global professional organization with focus upon antibody-based therapeutics.?CAS’s 2024 Annual Conference will take place in Cambridge, MA, USA, on Saturday, May 11, 2024. The theme of this conference is “Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories". You are welcome to register for the conference right NOW via the following link. https://lnkd.in/ecmFPA4v ? #biologics #antibody #antibodies #antibodydiscovery #antibodytherapeutics #mab #mabs #annualmeeting #annualconference

Unlocking the potential of antibody drugs for G-protein Coupled Receptors (GPCRs) Before us, there had been only three GPCRs for which antibody agonists have been discovered or engineered. We’ve already unlocked two more. +++ Abalone Bio is excited to share our poster from the recent “3rd GPCRs-Targeted Drug Discovery Summit” in Boston describing two sets of GPCR antibody agonists we've discovered using our Functional Antibody Selection Technology (FAST) platform. GPCRs are involved in regulating all areas of biology, and activators of many of them could treat hundreds of diseases. Antibody agonists combine the high specificity of antibodies with the ability to go beyond mere binding and activate target function with fewer off-target effects, but they are extremely rare. Abalone Bio’s FAST platform directly measures the function of 100 million antibodies simultaneously to both uncover rare agonists and fuel state-of-the-art protein large language models to predict even more. For CB2 antibody agonists, we show in vitro activity and, in collaboration with the Hohmann lab at Indiana University Bloomington, in vivo efficacy in a mouse model of peripheral neuropathy. We also show in vitro data for a range of potent agonists identified for another undisclosed GPCR.? (Not shown due to space constraints are great anti-inflammatory data from ex vivo studies using human liver slices from our collaboration with Scott Friedman's lab at Icahn School of Medicine at Mount Sinai.) We're excited to develop many more fully functional antibody therapeutics to access challenging targets and unlock much-needed therapeutic options for patients. Kudos to the Abalone Bio team for this outstanding work, and thanks to our many collaborators and advisors, investors (Y Combinator, BoxOne Ventures, Metaplanet, Gravity Fund, Leslie Ventures, Gaingels, Pioneer Fund, Jeff Dean, and others), and the The National Institutes of Health and National Science Foundation (NSF) SBIR programs for their support. Find out more about our work at https://www.abalonebio.com. #GPCR, #drugdiscovery, #biotech, #antibody, #AIDrugDiscovery, #MachineLearning, #therapeutics, #synbio

Just re-reading Ray Kurzweil's Singularity is Near, which highlights humans' difficulty in perceiving exponential growth. The work by Richard Yu and the late Gustavo Pesce's Abalone Bio to recursively design functional GPCR agonists using their FAST screen augmented with machine learning is what the early stages of that exponential growth looks like. Check out figure 2 and see if you don't agree that this is a breakthrough.

?????????????? ???? ?????????????????? ???????????????? #biotech ?????????? ???????? ?????????? ?? ?? Biogen to acquire HI-Bio for $1.8B, getting their lead candidate felzartamab, a monoclonal antibody for treatment of nephropathy and AMR ?? Johnson & Johnson announces acquisition of Proteologix for $850M, adding bispecific antibodies treating atopic dermatitis to portfolio ?? Uniquity Bio emerges from stealth with $300M, with lead candidate solrikitug, a monoclonal antibody targeting TSLP ?? Attovia Therapeutics secures $105M Series B for development of bispecific antibodies that use a proprietary spatial positioning technology ?? Pheon Therapeutics raises $120M in Series B to advance ADCs for hard-to-treat cancers, including lead program DAR8 with topoisomerase-1 inhibitor payload ?? AltruBio Inc. receives $225M in Series B to advance lead candidate, an immune checkpoint enhancer PSGL agonist antibody, for treatment of ulcerative colitis ?? London-based LabGenius raises over €40.1M to further develop its ML-driven antibody discovery platform ?? Bluejay Therapeutics granted $182M in Series C to accelerate development of IgG1 monoclonal antibody against hepatitis B surface antigen ?? AstraZeneca plans $1.5B manufacturing facility for antibody drug conjugates (ADCs) in Singapore ?? A-Alpha Bio receives additional $14.5M from the Department of Defense to accelerate antibody discovery ?? Royalty Pharma pays $525M for royalties ImmuNext’s frexalimab, an anti-CD40 monoclonal antibody for multiple sclerosis #Biointron #Antibodies #Immunotherapy #PharmaNews #Healthcare #DrugDevelopment #DrugDiscovery #Oncology #Innovation #Networking

I'm excited to share Abalone Bio's advancements in our platform for the discovery of agonist antibodies against GPCRs. Since it is extremely challenging to find functionally active antibodies against GPCRs, especially agonists, we are very excited to have generated potent antibody agonists against multiple targets, including CB2. CB2 is a difficult target because the cannabinoid binding site is buried, and so our antibodies likely activate the receptor by generating an active receptor conformation through interaction with the extracellular loops. In our poster below, we used machine learning models to predict dozens of novel agonist antibodies against our target receptor CB2. Since our platform directly selects for functionally active antibodies, we have millions of data points from these selections to train robust protein large language models that we have shown to be highly successful in the discovery of novel agonist antibodies. I'd like to express my thanks to the Abalone Bio team, our collaborators, advisors, investors and supporters for their contributions toward these achievements.

Over the past two years I've spoken with dozens of antibody drug developers at different pharmaceutical and biotechnology companies, and the number one request is for discovery tools for "multicell assays" to screen antibodies that bind antigens present in cell membranes. I'm excited to share the first results showing an elegant workflow to conduct these multicell assays in #nanovials, to screen tens to hundreds of thousands of plasma cells (cell 1) for antibodies that bind antigens on target cells (cell 2) - like PD-1 on immune cells. This is all done with standard fluorescence-activated cell sorters, with the highest intensity events corresponding to the best cell binders. This type of assay is very challenging since other direct B cell screening approaches, like antigen baiting, or repertoire sequencing, do not characterize binding of antibodies to cell membranes. Often teams are relegated to hybridoma workflows, where clones are grown up for weeks and hundreds of wells are screened one at a time for cell binders. Alternatively, if recombinant antigen is available, memory B cell screening can yield binders that all have to be sequenced, re-expressed, and tested one by one for subsequent cell binding. Less accessible microfluidic tools can also be used for direct screening of antibody-secreting cells, but are limited in throughput. Many thanks to Dilip Challa and Jennifer Watkins-Yoon for initially leading the studies in the pre-print and to PJ Krohl, Cassady Konu, and Kent Bondensgaard for their continued support and efforts to develop multicell assays with the Partillion Bioscience team, including Joe de Rutte, Shreya Udani, Jesse Liang, and Ronald Rondon. Please feel free to reach out to Partillion Bioscience if you are interested in trying out this new workflow for your own discovery campaigns. I think this is just the start of many other possible multicell workflows using Nanovials: including cell signaling reporter assays, viral neutralization assays, T cells interacting with antigen-presenting cells to evaluating the function of multispecific antibodies. Stay tuned! #biotechnology #antibodydiscovery #mabs #antibodies #plasmacells #bioengineering #drugdiscovery #flowcytometry #cytometry #singlecell #labonaparticle https://lnkd.in/giDhk2MS

Biocytogen and Acepodia, announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. This collaboration combines Biocytogen’s RenLite? platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology to tackle some of the toughest challenges in oncology—tumor heterogeneity and drug resistance. This novel approach aims to address these complexities by utilizing dual-payloads that target multiple therapeutic or disease pathways. These payloads are delivered with bispecific antibodies that enable enhanced precision and functionality. To share your startup story write us on - [email protected] #Biocytogen #Acepodia

Super proud of the Abalone Bio team for all the amazing work behind this poster on Abalone Bio’s Functional Antibody Selection Technology (FAST) discovery platform and the GPCR antibody agonists it discovers and designs. As the company post says, there have only ever been three GPCRs for which antibody agonists have been discovered or engineered, and we’ve unlocked two more. The real drop-the-coffee-cup moment for me was in predicting dozens of CB2 GPCR agonists using a protein large language model fueled by FAST platform data. As a card-carrying structural biologist (issued in 2000- I’m pretty sure it’s still valid), I know the protein sequence-function landscape can be rough- a single amino acid mutation can disrupt an antibody’s binding or pharmacological activity. We hypothesized the FAST datasets would be large enough to map out this rugged landscape with sufficient resolution to capture the predictive information within, particularly when coupled to the structural priors brought by a protein language model pre-trained on millions of antibody sequences. For the receptors we’ve worked on so far, that appears to be true. Kudos to this work's many contributors and collaborators, and bottomless thanks to our advisors, investors, and supporters. Reach out if you’d like to learn more about our work, and find out more at https://www.abalonebio.com. #GPCR, #drugdiscovery, #biotech, #antibody, #AIDrugDiscovery, #MachineLearning, #therapeutics, #synbio https://lnkd.in/gf3jbyye